What’s ahead for Eli Lilly and Novo as RFK Jr. takes over HHS
Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock face investor scrutiny as RFK Jr. takes the leadership of HHS. Read more ...
Jim Cramer Backs Eli Lilly (LLY): Will Its Drug Pipeline Dominate Pharma?
We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...
FierceBiotech12d
Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
STAT12d
AstraZeneca offers some reassurance on China challenges
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...
FierceBiotech12d
UPDATED: Eli Lilly lops Alzheimer's and obesity assets from pipeline in Q4 update
In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...
Irish Examiner15d
Ireland's small, open economy is about to be put to the test
According to the CSO, €41.1bn of those exports were medicinal and pharmaceutical ... particularly from the US. Pfizer, Eli Lilly, Johnson & Johnson, Stryker, Bausch + Lomb, Regeneron and Abbvie are ...
Nasdaq21d
What Does the Future Hold for Eli Lilly?
With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.
FiercePharma22d
Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief
Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...